Currently there are no approved therapies for lung transplant recipients in the United States (US). Treatment with CIS following lung transplantation has previously been demonstrated to result in a clinically meaningful improvement in survival and chronic rejection-free survival compared to placebo, but additional data supporting its use is needed prior to Food and Drug Administration (FDA) approval. This treatment use protocol is a mechanism for providing eligible lung transplant recipients early access to CIS in advance of FDA approval.

Inclusion Criteria:

• Single-or double-lung transplant recipients who have a high risk for developing chronic rejection
• Single or double-lung transplant recipients who have developed chronic rejection
• Single or double-lung transplant recipients who have serious or life-threatening complications of systemic immunosuppressive therapy

Exclusion Criteria:

• Known hypersensitivity to cyclosporine or propylene glycol (PG)
• Females who are pregnant or are considering becoming pregnant
• Females who are breast feeding a child.